Kitchener, Ontario – April 20th, 2026 – Medical Innovation Xchange (MIX) is proud to welcome NodeAI as the newest affiliate company in our expanding community of Canadian med‑tech innovators. Based in Hamilton, NodeAI is advancing a critical area of lung cancer care with software‑as‑a‑medical‑device (SaMD) solutions designed to enhance the accuracy and accessibility of endobronchial ultrasound (EBUS). 

NodeAI is focused on transforming EBUS, a cornerstone technique for lung cancer staging that requires significant expertise to perform well. Variability in clinician experience can impact diagnostic accuracy, procedure efficiency, and ultimately patient outcomes. NodeAI’s mission is to close that gap. 

With NodeAIPredict and NodeAIGuide, the company provides real‑time AI support that helps clinicians identify lymph nodes more easily and assess malignancy risk during the procedure. By simplifying a complex workflow and augmenting clinical decision‑making, Node AI aims to reduce variability, support more consistent staging, and expand access to high‑quality lung cancer care. 

This technology brings expert‑level assistance directly to the point of care, empowering more providers to deliver precise, timely, and confident EBUS assessments, especially in settings where specialized expertise may be limited. 

By joining MIX, NodeAI gains access to a community uniquely equipped to support the development and commercialization of regulated medical technologies. 

As they continue advancing their platform, NodeAI is committed to improving lung cancer care by making expert‑level EBUS support more widely accessible. 

MIX is thrilled to welcome NodeAI to our ecosystem and to support their journey toward meaningful clinical impact. Their mission aligns deeply with our vision for advancing Canadian med‑tech innovation. 

Learn more about MIX or explore how to join our community by visiting MIX Programs.